68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Status Active, not recruiting

Clinical Trial Summary

This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin positron emission tomography (PET)/magnetic resonance imaging (MRI) in imaging patients with prostate cancer. PET uses a radioactive substance called 68Ga-DOTA-Bombesin, which attaches to tumor cells with specific receptors on their surfaces. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy prostate tissue. MRI uses radio waves and a magnet to make a picture of areas inside the body. Using 68Ga-DOTA-Bombesin in diagnostic procedures, such as PET/MRI, may allow doctors to identify smaller tumors than standard imaging.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the feasibility and biodistribution of 68Ga-DOTA-Bombesin (BAY 86-7548 or 68Ga-DOTA RM2).

OUTLINE:

Patients receive 68Ga-DOTA-Bombesin intravenously (IV) and then undergo PET/MRI approximately 60 later.

After completion of study, patients are followed up at 24 hours and 1 week. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02440308
Study type	Interventional
Source	Stanford University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 2015
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04457232` - Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation	Phase 1
Active, not recruiting	`NCT03661437` - Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy	Early Phase 1
Completed	`NCT02337465` - KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer	N/A
Completed	`NCT03013413` - Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy	N/A
Recruiting	`NCT06037863` - Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial	N/A
Active, not recruiting	`NCT03580499` - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy	N/A
Completed	`NCT03326440` - Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer	N/A
Recruiting	`NCT04597359` - To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring	Phase 2
Active, not recruiting	`NCT03263650` - Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC	Phase 2
Active, not recruiting	`NCT04600336` - Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer	Phase 2
Active, not recruiting	`NCT04299620` - Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy	N/A
Completed	`NCT04976257` - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion	Early Phase 1
Completed	`NCT02957981` - The Genetic Education for Men Trial: Web-Based Education vs. Standard Care	N/A
Withdrawn	`NCT03408561` - Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer	N/A
Enrolling by invitation	`NCT06347809` - DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Enrolling by invitation	`NCT04254133` - Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
Recruiting	`NCT05519878` - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers	N/A
Recruiting	`NCT02994758` - Development of Diagnostics and Treatment of Urological Cancers	N/A
Completed	`NCT01497431` - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants	Phase 1
Active, not recruiting	`NCT00002540` - Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)	N/A